Advances in psoriasis therapy.
Koo
J
J
Department of Dermatology, University of California, San Francisco Medical Center, USA.
Nguyen
Q
Q
Gambla
C
C
D000042:Absorption; D017255:Acitretin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D000279:Administration, Cutaneous; D002117:Calcitriol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D002626:Chemistry, Pharmaceutical; D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D007641:Keratolytic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D009824:Ointments; D011565:Psoriasis / Q000188:drug therapy*
D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D007641:Keratolytic Agents; D009824:Ointments; C055085:calcipotriene; D016572:Cyclosporine; D002117:Calcitriol; D017255:Acitretin